Skip to main content
. 2006 Sep 27;4:17. doi: 10.1186/1477-9560-4-17

Table 4.

Incidence of venous thromboembolism among medical inpatients receiving enoxaparin versus UFH prophylaxis by dosage and duration of prophylaxis received

Outcome (N [%])

Prophylaxis Received/Dosage or Days N % of Patients DVT PE VTE (DVT and/or PE)
Dosage:
 Enoxaparin
  30–40 mg 186 38.8% 0 (0.0) 0 (0.0) 0 (0.0)
  50–60 mg 293 61.2% 8 (2.7) 0 (0.0) 8 (2.7)
 UFH
  5,000-<10,000 IU 414 14.5% 47 (11.4) 8 (1.93) 52 (12.6)
  10,000 IU 2,221 78.0% 109 (4.9) 23 (1.04) 121 (5.4)
  >10,000–15,000 IU 214 7.5% 7 (3.3) 1 (0.5) 7 (3.3)
Prophylaxis days:
 Enoxaparin
  1–2 days 74 15.4% 4 (5.4) 0 (0.0) 4 (5.4)
  3–4 days 36 7.5% 2 (5.6) 0 (0.0) 2 (5.6)
  5–6 days 123 25.7% 2 (1.6) 0 (0.0) 2 (1.6)
  > 6 days 246 51.4% 0 (0.0) 0 (0.0) 0 (0.0)
 UFH
  1–2 days 831 29.3% 109 (13.1) 22 (2.7) 120 (14.4)
  3–4 days 227 8.0% 21 (9.25) 2 (0.9) 23 (10.1)
  5–6 days 608 21.4% 15 (2.5) 4 (0.7) 15 (2.5)
  > 6 days 1,171 41.3% 18 (1.5) 4 (0.3) 22 (1.9)

Bold indicates p for trend <0.05